Literature DB >> 1929295

In vitro activity of YM133, a new semisynthesized macrolide.

T Terasawa1, M Watanabe, T Okubo, S Mitsuhashi.   

Abstract

YM133, the 4"-O-(4-methoxyphenyl)acetyltylosin, is a new macrolide. The in vitro activity of YM133 was compared with those of erythromycin, josamycin, and rokitamycin by an agar dilution method. YM133 inhibited 90% of the tested isolates of Streptococcus pneumoniae, Legionella spp., and anaerobic bacteria at less than or equal to 1.56 micrograms/ml. The drug inhibited 90% of erythromycin-resistant staphylococci and Streptococcus pyogenes at less than or equal to 50 micrograms/ml. YM133 showed activity against erythromycin-, josamycin-, and rokitamycin-resistant (MIC greater than or equal to 100 micrograms/ml) strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp. Enterococci were less susceptible to other YM133-like macrolides. Unlike other macrolides, YM133 showed killing activity, and the MBC/MIC ratios of YM133 for several strains were 1:32, whereas those of erythromycin were 4:1,024. In a time-kill curve study, the reduction of viable cells started within 2 h after the addition of YM133.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929295      PMCID: PMC245174          DOI: 10.1128/AAC.35.7.1370

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.

Authors:  A Tamura; R Okamoto; T Yoshida; H Yamamoto; S Kondo; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

2.  4''-O-(4-methoxyphenyl)-acetyltylosin, a new macrolide derivative of therapeutic importance.

Authors:  T Takeuchi; T Sawa; H Naganawa; M Hamada; H Umezawa; T Yoshioka; K Kiyoshima; H Iguchi; M Sakamoto; Y Shimauchi
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

3.  The activity of 4''-acylated tylosin derivatives against macrolide-resistant gram-positive bacteria.

Authors:  R Okamoto; H Nomura; M Tsuchiya; H Tsunekawa; T Fukumoto; T Inui; T Sawa; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1979-05       Impact factor: 2.649

4.  Synthesis and structure-activity studies of new 4''-O-acyltylosin derivatives of therapeutic interest.

Authors:  T Yoshioka; K Kiyoshima; M Maeda; M Sakamoto; T Ishikura; Y Fukagawa; T Sawa; M Hamada; H Naganawa; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1988-11       Impact factor: 2.649

5.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Studies of tylosin derivatives effective against macrolide-resistant strains: synthesis and structure-activity relationships.

Authors:  M Tsuchiya; M Hamada; T Takeuchi; H Umezawa; K Yamamoto; H Tanaka; K Kiyoshima; S Mori; R Okamoto
Journal:  J Antibiot (Tokyo)       Date:  1982-06       Impact factor: 2.649

7.  Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

Authors:  N X Chin; N M Neu; P Labthavikul; G Saha; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

8.  Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors.

Authors:  P C Taylor; F D Schoenknecht; J C Sherris; E C Linner
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  1 in total

Review 1.  Clostridium difficile drug pipeline: challenges in discovery and development of new agents.

Authors:  Angie M Jarrad; Tomislav Karoli; Mark A T Blaskovich; Dena Lyras; Matthew A Cooper
Journal:  J Med Chem       Date:  2015-03-30       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.